Search research articles
Contact Us
Filters
Showing results (21-30 of 134) with videos related to
Page
of 14
Sort By:
Biorxiv : the Preprint Server for Biology
|
December 15, 2021
Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
John P Evans, Cong Zeng, Claire Carlin, et al.
Science Translational Medicine
|
February 15, 2022
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
John P Evans, Cong Zeng, Claire Carlin, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|
May 21, 2026
Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study
Tamanna Haque, Arletta Lozanski, Tzy-Jyye Doong, et al.
Haematologica
|
November 2, 2014
Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective
Leslie A Andritsos, Neil Dunavin, Gerard Lozanski, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
January 23, 2017
Computer-assisted quantification of CD3+ T cells in follicular lymphoma
Fazly S Abas, Arwa Shana'ah, Beth Christian, et al.
Blood
|
October 11, 2014
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
Jennifer A Woyach, Farrukh Awan, Ian W Flinn, et al.
Haematologica
|
December 2, 2021
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu, Jessica K Altman, Geoffrey L Uy, et al.
Blood
|
October 31, 2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks, Beth Christian, Samantha Jaglowski, et al.
Ejhaem
|
November 29, 2023
Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2
Kaitlin Annunzio, Michael Ozga, Ying Huang, et al.
Mbio
|
November 2, 2021
Erratum for Zeng et al., "Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H"
Cong Zeng, John P Evans, Julia N Faraone, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 134) with videos related to
Sort By:
Page
of 14
Biorxiv : the Preprint Server for Biology
|
December 15, 2021
Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
John P Evans, Cong Zeng, Claire Carlin, et al.
Science Translational Medicine
|
February 15, 2022
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
John P Evans, Cong Zeng, Claire Carlin, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|
May 21, 2026
Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study
Tamanna Haque, Arletta Lozanski, Tzy-Jyye Doong, et al.
Haematologica
|
November 2, 2014
Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective
Leslie A Andritsos, Neil Dunavin, Gerard Lozanski, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
January 23, 2017
Computer-assisted quantification of CD3+ T cells in follicular lymphoma
Fazly S Abas, Arwa Shana'ah, Beth Christian, et al.
Blood
|
October 11, 2014
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
Jennifer A Woyach, Farrukh Awan, Ian W Flinn, et al.
Haematologica
|
December 2, 2021
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu, Jessica K Altman, Geoffrey L Uy, et al.
Blood
|
October 31, 2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks, Beth Christian, Samantha Jaglowski, et al.
Ejhaem
|
November 29, 2023
Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2
Kaitlin Annunzio, Michael Ozga, Ying Huang, et al.
Mbio
|
November 2, 2021
Erratum for Zeng et al., "Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H"
Cong Zeng, John P Evans, Julia N Faraone, et al.
Page
of 14